ISSN Print: 2472-9574  ISSN Online: 2472-9590
International Journal of Chemical and Biomedical Science  
Manuscript Information
 
 
The Role of Arachidonic Acid Metabolites (Endocannabinoids and Eicosanoids) in the Immune Processes: A Review
International Journal of Chemical and Biomedical Science
Vol.1 , No. 3, Publication Date: Jun. 12, 2015, Page: 70-78
1551 Views Since June 12, 2015, 2461 Downloads Since Jun. 12, 2015
 
 
Authors
 
[1]    

Yulia K. Denisenko, Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitation Treatment, Vladivostok, Russia.

[2]    

Elena G. Lobanova, Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitation Treatment, Vladivostok, Russia.

[3]    

Tatyana P. Novgorodtseva, Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitation Treatment, Vladivostok, Russia.

[4]    

Tatyana A. Gvozdenko, Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitation Treatment, Vladivostok, Russia.

[5]    

Anna V. Nazarenko, Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Medical Climatology and Rehabilitation Treatment, Vladivostok, Russia.

 
Abstract
 

This review is devoted to the modern concepts of arachidonic acid metabolites – endocannabinoids and eicosanoids. We discussed their biosynthetic pathways, the interaction mechanisms and the role in the immune response. The results of our research on the endocannabinoid system and on the role of eicosanoids in the inflammatory process are given. We found that the synthetic ligands of cannabinoid receptors (WIN 55,212-2 and anandamide) dose-dependently inhibit the lipoxygenase pathway of the pro-inflammatory leukotriene B4 and the ability of the immune cells to express IL-2, IL-8, and TNF-α. The activities of the immune and the endocannabinoid systems have the reciprocal relationship which is characterized by the decrease in the СВ2 receptor expression and the activation of immune mechanisms. The obtained results on the role of endocannabinoid system in the regulation of the immune response are contributing to the understanding of molecular and cell mechanisms of inflammation development.


Keywords
 

Endocannabinoid, Eicosanoid, the Immune system


Reference
 
[01]    

Battista N, Tommaso M, Bari M, Maccarrone M: The endocannabinoid system: an overview. Front Behav Neurosci 2012, 6:9.

[02]    

Di Marzo V: Endocannabinoids: synthesis and degradation. Physiol Biochem Pharmacol 2008, 160:1289–1296.

[03]    

Fonseca RF, Arco DI, Bermudez-Silva FJ: The endocannabinoid system: physiology and pharmacology. Alcohol 2005, 40(1):2-14.

[04]    

Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A:Beta-caryophyllene is a dietary cannabinoid. PNAS 2008, 105(26):9099-9104.

[05]    

Mechoulam R, Fride E, Di Marzo V: Endocannabinoids. Eur J Pharmacol 1998, 359:1-18.

[06]    

Smith ML, Murphy RC: The eicosanoids: cyclooxygenase, lipoxygenase and epoxygenase pathways. In Biochemistry of lipids, lipoproteins and membranes. 4th edition. Edited by Vance DE, Vance JE. Amsterdam: Elsevier Science; 2002:341-371.

[07]    

Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology.Science2001, 294:1871-1875.

[08]    

Gilroy DW: Eicosanoids and the endogenous control of acute inflammatory resolution. Int J Biochem Cell Biol 2010, 42(4):524-528.

[09]    

Samuelsson B, Goldyne M, Granström E, Hamberg M, Hammarström S, Malmsten C: Prostaglandins and thromboxanes. Annu Rev Biochem 1978, 47:997-1029.

[10]    

Tapiero H, Nguyen B, Couvreur G: Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed. Pharmacother. 2002, 56:215–222.

[11]    

Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.

[12]    

Katona S, Kaminski E, Sanders H, Zajicek J: Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 2005, 140(3):580–585.

[13]    

Klein TW, Newton C, Friedman H: Cannabinoid receptors and the cytokine network. Adv Exp Med Biol 1998, 437: 215-222.

[14]    

Márquez L, Abanades S, Andreu M: Endocannabinoid system and bowel inflammation. Med. Clin.(Barc) 2008, 131(13):513-517.

[15]    

Sergeeva MG, Varfolomeeva AT: Arachidonic acidcascade. Moscow: Public education; 2006.

[16]    

Brash AR: Arachidonic acid as a bioactive molecule. J Clin Invest 2001, 107:1339-1345.

[17]    

Rouzer CA, Marnett LJ: Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways. Chem Rev 2011, 111(10):5899–5921.

[18]    

Bergström S, Danielsson H, Samuelsson B: Enzymic formation of prostaglandin E2 from arachidonic acid. Biochim Biophys Acta 1964, 90:207-210.

[19]    

Van Dorp DA, Beerthuis RK, Nugeteren DH, Vonkeman H: The biosynthesis of prostaglandins.Biophys Acta 1964, 90:204-207.

[20]    

Giuffrida A, Beltramo M, Piomelli D: Mechanisms of Endocannabinoid Inactivation: Biochemistry and Pharmacology. J Pharmacol Exp Ther 2001, 298:7-14.

[21]    

Spector AA: Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 2009, 50:59–65.

[22]    

Goldyne ME, Burrish GF, Poubelle P, Borgeat P: Arachidonic acid metabolism among human mononuclear leukocytes. Lipoxygenase-related pathways. J Biol Chem 1984, 259:8815–8819.

[23]    

Lewis RA, Austen KF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Eng. J Med 1990, 323:645-655.

[24]    

Murakami M: Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:783-792.

[25]    

Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996, 271:157-160.

[26]    

Dixon RA: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990, 343:282–284.

[27]    

Gaoni Y, Mechoulam R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646-1647.

[28]    

Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.

[29]    

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.

[30]    

Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.

[31]    

Farquhar-Smith WP, Jaggar SI, Rice AS: Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors.Pain2002, 97:11-21.

[32]    

Pertwee RG, Ross RA: Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002, 66(2,3):101-121.

[33]    

Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayerwitch M, Barg J, Vogel Z: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995,50:83-90.

[34]    

Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain. Biochem Biophys Res Commun 1995, 215:89-97.

[35]    

Wang J, Ueda N: Biology of endocannabinoid synthesis system. Prostaglandins & Other Lipid Mediators 2009, 89:112-119.

[36]    

Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001, 98(16):9371-9376.

[37]    

Brenowitz SD, Regehr WG: Calcium dependence of retrograde inhibition by endocannabinoids at synapses in to purkinje cells. J Neurosci 2003, 23:6373-6384.

[38]    

Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D:Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Pancreas 2004, 5:41-43.

[39]    

Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K, Takizawa H, Nagano T: Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1995, 1254:127-134.

[40]    

Hampson AJ, Hill WA, Zan-Phillips M, Makriyannis A, Leung E, Eglen RM, Bornheim LM: Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta 1995, 16:173-179.

[41]    

Forsell PK, Brunnström A, Johannesson M, Claesson HE: Metabolism of anandamide into eoxamides by 15-Lipoxygenase-1 and glutathione transferases. Lipids 2012,47(8):781-791.

[42]    

Yu M, Ives D, Ramesha CS: Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase - 2. J Biol Chem 1997, 272 : 21181- 21186.

[43]    

Narumiya S, Fitzgerald GA: Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25 - 30.

[44]    

Bornheim LM, Kim KY, Chen B, Correia MA: The effect of cannabidiol on mouse hepatic microsomal cytochrome P450 - dependent anandamide metabolism. Biochem Biophys Res Commun 1993, 197: 740- 746.

[45]    

Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V: Influence of fatty acid ethanolamides and 9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 1997, 330: 231-240.

[46]    

Racz I, Göthert M, Zimmer A: Anandamide effects on 5-HT3 receptors in vivo. Europ J Pharmacol 2008, 596:98-101.

[47]    

Lobanova EG: Effect of syntheticcannabinoid receptorligandson the expression of eicosanoids in vitro. Bull RAMS 2012, 32(2) : 5- 8.

[48]    

Diaz S, Specter S, Volanderhoek JY,Coffey RG:The effect of delta-9-tetrahydrocannabinol on arachidonic acid metabolism in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 1994, 268:1289–1296.

[49]    

Soberman RJ, Christmas P: The organization and consequences of eicosanoid signaling. Clin Invest 2003, 111(8):1107-1113.

[50]    

Snider NT, Kornilov AM, Kent UM, Hollenberg PF: Anandamide Metabolism by Human Liver and Kidney Microsomal Cytochrome P450 Enzymes to Form Hydroxyeicosatetraenoic and Epoxyeicosatrienoic Acid Ethanolamides. J Pharmacol Exp Ther 2007, 321: 590-597.

[51]    

Krylatov AV, Uzhachenko RV, Maslov LN, Ugdyzhekova DS, Bernatskaia NA, Pertwee R, Stefano GB, Makriyannis A: Anandamide and R-(+) metanandamid prevent the development of ischemic and reperfusion arrhythmias in rats by stimulating the CB2 receptor Eksp Klin Farmakol 2002,3:6-9.

[52]    

Churyukanov MV, Churyukanov VV: Functional organizationand the therapeutic potential of the endogenous cannabinoid system. Experand clinicalpharmacology 2004, 67(2): 70- 78.

[53]    

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84-87.

[54]    

Habayeb OM, Taylor AH, Bell SC, Taylor DJ, Konje JC: Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. Endocrinology 2008, 149(10):5052–5060.

[55]    

Hiley CR: Endocannabinoids and the heart. J CardioVolasc Pharmacol 2009, 53(4):267–276.

[56]    

Pertwee RG: Pharmacological actions of cannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg, Springer-Verlag; 2005, 168:1-51.

[57]    

Robson P: Therapeutic aspects of cannabis and cannabinoids.Br J Psychiatry 2001, 178:107-115.

[58]    

Farquhar-Smith WP, Rice AS:Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 2001, 94:507-513.

[59]    

Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB: Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol. 1998, 54(1):180-8.

[60]    

Lobanova (Isachenko) EG, Vitkina TI, Berdyshev EV: The influence of ligands of cannabinoid receptors WIN 55, 212 – 2 and anandamide on TNF-a production, and IL-8 blood leukocytes of healthy individuals and patients with allergy. Immunopathology, Allergology, Infectology 2003, 2:86-91.

[61]    

Lobanova EG: Effect of cannabinoid receptor ligands on the reactivity of immune cells. Germany: Lambert Academic Publishing; 2011.

[62]    

Lobanova EG: Effect of synthetic cannabinoid receptor ligands on the reactivity of immune cells in vitro. Med Immunology 2009, 11(2-3):261-264.

[63]    

Bueb JL, Lambert DM, Tschirhart EJ: Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim Biophys Acta 2001, 1538:252-259.

[64]    

Lobanova EG: Role of endocannabinoid receptors in the regulation of immune response. Med Immunology 2012, 14(3) :189-194.





 
  Join Us
 
  Join as Reviewer
 
  Join Editorial Board
 
share:
 
 
Submission
 
 
Membership